Klin Farmakol Farm. 2017;31(1):15-18 | DOI: 10.36290/far.2017.004

Current opinion in epidemiology and approaches to the treatment of viral hepatitis A and E.

Matúš Mihalčin1, 2, Lenka Fašaneková1, 2, Petr Husa ml.1, 2, Petr Husa1, 2
Lékařská fakulta Masarykovy Univerzity, Brno; 1
Klinika infekčních chorob, Fakultní nemocnice Brno; 2

Viral hepatitis A and E share some epidemiological and clinical characteristics, thus are often associated as related diseases. New
discoveries in the last decade, particularly for hepatitis E, change the view on these diseases. The review describes the specifics
of each disease and current possibilities of pharmacological intervention on the clinical course of the disease caused by hepatitis
A virus (HAV) and hepatitis E virus (HEV).

Keywords: hepatitis A, HAV, hepatitis E, HEV, review.

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mihalčin M, Fašaneková L, Husa P, Husa P. Current opinion in epidemiology and approaches to the treatment of viral hepatitis A and E. Klin Farmakol Farm. 2017;31(1):15-18. doi: 10.36290/far.2017.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kasper DL, Fauci AS, Hauser SL, Longo DL. Harrison's Principles of Internal Medicine. 19th edition. New York: McGraw-Hill Education 2015.
    2. Aggarwal R, Kamili S, Spelbring J, Krawczynski K. Experimental studies on subclinical hepatitis E virus infection in cynomolgus macaques. J Infect Dis 2001; 184(11): 1380-1385. Go to original source... Go to PubMed...
    3. Kamar N, Izopet J, Cintas P, Garrouste C, Uro-Coste E, Cointault O, et al. Hepatitis E Virus-Induced Neurological Symptoms in a Kidney-Transplant Patient with Chronic Hepatitis. Am J Transplant 2010; 10(5): 1321-1324. Go to original source... Go to PubMed...
    4. Shrestha MP, Scott RM, Joshi DM, Mammen MP, Thapa GB, Thapa N, et al. Safety and Efficacy of a Recombinant Hepatitis E Vaccine. N Engl J Med 2007; 356(9): 895-903. Go to original source... Go to PubMed...
    5. Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. The Lancet 2010; 376(9744): 895-902. Go to original source... Go to PubMed...
    6. Park SB. Hepatitis E vaccine debuts. Nature 2012; 491(7422): 21-22. Go to original source... Go to PubMed...
    7. Yoon EL, Yim HJ, Kim SY, Kim JH, Lee J-H, Lee YS, et al. Clinical courses after administration of oral corticosteroids in patients with severely cholestatic acute hepatitis A; three cases. Korean J Hepatol 2010; 16(3): 329-333. Go to original source... Go to PubMed...
    8. Mathurin P. The use of corticosteroids in severe alcohol hepatitis: We need to look beyond this controversy. J Hepatol 2010; 53(2): 392-393. Go to original source... Go to PubMed...
    9. Madrigal-Santillán E, Madrigal-Bujaidar E, Álvarez-González I, Sumaya-Martínez MT, Gutiérrez-Salinas J, Bautista M, et al. Review of natural products with hepatoprotective effects. World J Gastroenterol 2014; 20(40): 14787-14804. Go to original source... Go to PubMed...
    10. Hong M, Li S, Tan H, Wang N, Tsao S-W, Feng Y. Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects. Int J Mol Sci 2015; 16(12): 28705-28745. Go to original source... Go to PubMed...
    11. Seo DJ, Lee M, Jeon SB, Park H, Jeong S, Lee B-H, et al. Antiviral activity of herbal extracts against the hepatitis A virus. Food Control 2017; 72(Part A): 9-13. Go to original source...
    12. Ferenci P. Silymarin in the treatment of liver diseases: What is the clinical evidence? Clin Liver Dis 2016; 7(1): 8-10. Go to original source... Go to PubMed...
    13. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, et al. Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. Gastroenterology 2011; 140(5): 1481-1489. Go to original source... Go to PubMed...
    14. Behrendt P, Steinmann E, Manns MP, Wedemeyer H. The impact of hepatitis E in the liver transplant setting. J Hepatol 2014; 61(6): 1418-1429. Go to original source... Go to PubMed...
    15. Debing Y, Neyts J. Antiviral strategies for hepatitis e virus. Antiviral Res 2014; 102: 106-118. Go to original source... Go to PubMed...
    16. Wang Y, Metselaar HJ, Peppelenbosch MP, Pan Q. Chronic hepatitis E in solid-organ transplantation: the key implications of immunosuppressants. Curr Opin Infect Dis 2014; 27(4): 303-308. Go to original source... Go to PubMed...
    17. Péron JM, Abravanel F, Guillaume M, Gérolami R, Nana J, Anty R, et al. Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. Liver Int Off J Int Assoc Study Liver 2016; 36(3): 328-333. Go to original source... Go to PubMed...
    18. Peters van Ton AM, Gevers TJG, Drenth JPH. Antiviral therapy in chronic hepatitis E: a systematic review. J Viral Hepat 2015; 22(12): 965-973. Go to original source... Go to PubMed...
    19. van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology 2014; 82(6): 491-497. Go to original source... Go to PubMed...
    20. Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, et al. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. Gastroenterology 2016; 150(1): 82-85.e4. Go to original source... Go to PubMed...
    21. van der Valk M, Zaaijer HL, Kater AP, Schinkel J. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J Hepatol 2017; 66(1): 242-243. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.